Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Language
Document Type
Year range
1.
Int J Environ Res Public Health ; 19(12)2022 06 09.
Article in English | MEDLINE | ID: covidwho-1884188

ABSTRACT

Aspergillosis is a disease caused by Aspergillus, and invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection leading to death in severely immuno-compromised patients. The literature reports Aspergillus co-infections in patients with COVID-19 (CAPA). Diagnosing CAPA clinically is complex since the symptoms are non-specific, and performing a bronchoscopy is difficult. Generally, the microbiological diagnosis of aspergillosis is based on cultural methods and on searching for the circulating antigens galactomannan and 1,3-ß-D-glucan in the bronchoalveolar lavage fluid (bGM) or serum (sGM). In this study, to verify whether the COVID-19 period has stimulated clinicians to pay greater attention to IPA in patients with respiratory tract infections, we evaluated the number of requests for GM-Ag research and the number of positive tests found during the pre-COVID-19 and COVID-19 periods. Our data show a significant upward trend in GM-Ag requests and positivity from the pre-COVID to COVID period, which is attributable in particular to the increase in IPA risk factors as a complication of COVID-19. In the COVID period, parallel to the increase in requests, the number of positive tests for GM-Ag also increased, going from 2.5% in the first period of 2020 to 12.3% in the first period of 2021.


Subject(s)
COVID-19 , Invasive Pulmonary Aspergillosis , Pulmonary Aspergillosis , Aspergillus , Bronchoalveolar Lavage Fluid , COVID-19/epidemiology , Humans , Invasive Pulmonary Aspergillosis/complications , Invasive Pulmonary Aspergillosis/diagnosis , Invasive Pulmonary Aspergillosis/epidemiology , Pulmonary Aspergillosis/complications , Pulmonary Aspergillosis/diagnosis , Pulmonary Aspergillosis/epidemiology , Sensitivity and Specificity
2.
Antibiotics (Basel) ; 10(6)2021 May 29.
Article in English | MEDLINE | ID: covidwho-1256419

ABSTRACT

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as "rescue" treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had failed previous regimens. A total of 13 patients were treated from 1 September 2020 to 31 March 2021. In total, 5/13 (38%) patients were classified as critically ill, due to severe COVID-19 lung failure; 4/13 (31%) patients had post-surgical infections and 4/13 (31%) had severe infections in immunocompromised subjects due to solid organ transplantation (2/4) or hematological malignancy (2/4). Overall, 10/13 infections were caused by carbapenem-resistant Acinetobacter baumannii, one by KPC-positive ceftazidime/avibactam-resistant Klebsiella pneumonia and two by Pseudomonas aeruginosa XDR. Based on clinical, microbiological and hematobiochemical evaluation, cefiderocol was associated with different companion drugs, particularly with fosfomycin, high-dose tigecycline and/or colistin. Microbiological eradication was achieved in all cases and the 30-day survival rate was 10/13; two patients died due to SARS-CoV-2 lung failure, whereas one death was attributed to subsequent infections. No recurrent infections within 30 days were reported. Finally, we hereby discuss the therapeutic potential of cefiderocol and the possible place in the therapy of this novel drug.

3.
Acta Biomed ; 91(4): e2020126, 2020 07 22.
Article in English | MEDLINE | ID: covidwho-1059504

ABSTRACT

BACKGROUND AND AIM OF THE WORK: COVID-19 is a current global pandemic. However, comprehensive global data analyses for its healthcare management are lacking. METHODS: In this study we have researched through published scientific articles and international health care  guidelines to find out actually about our knowledge for this new pandemic from SARS-CoV-2 and related COVID-19 disease that emerged from December 2019 in China in order to better manage this health emergency. RESULTS: The pathogens represented by microorganisms (bacteria, mycetes or viruses) show their effect after days and are responsible for epidemics/pandemics as dangerous as the greater their possibility of transmission, especially by inhalation, and therefore their infectivity. CONCLUSIONS: The appearance of new pathogenic viruses for humans such as the COVID -19, which previously were found only in the animal world occurs through the spillover (is the third documented of an animal coronavirus to humans), it is thought that it could also be the same also for the origin of this virus. Furthermore, the trend of this pandemic in one of the countries most affected by Italy after China was also considered.


Subject(s)
COVID-19/therapy , COVID-19/transmission , Communicable Disease Control , COVID-19/diagnosis , Humans
SELECTION OF CITATIONS
SEARCH DETAIL